SandboxAQ and MapLight Therapeutics Announce Strategic Collaboration to Discover and Develop Novel CNS Therapies
MapLight Therapeutics, Inc. (MPLT)
Company Research
Source: GlobeNewswire
SAN FRANCISCO and BOSTON, Dec. 16, 2025 (GLOBE NEWSWIRE) -- SandboxAQ and MapLight Therapeutics, Inc. (Nasdaq: MPLT) announced today that the companies have entered into a strategic collaboration to discover and develop potential first-in-class therapies targeting a novel G protein-coupled receptor (GPCR) for the treatment of central nervous system (CNS) disorders. Under the terms of the agreement, SandboxAQ received an upfront payment and will be eligible to receive additional preclinical, development, regulatory, and commercial milestone payments of up to $200 million in aggregate. The companies will jointly conduct preclinical research activities and MapLight will have exclusive rights for potential clinical development and commercialization of collaboration compounds. “We are excited to advance research efforts for this novel target that was identified and validated using our discovery platform,” said James Lillie, Chief Scientific Officer at MapLight. “We look forward to coll
Show less
Read more
Impact Snapshot
Event Time:
MPLT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MPLT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MPLT alerts
High impacting MapLight Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
MPLT
News
- Maplight Therapeutics (NASDAQ:MPLT) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=MPLT&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StrMarketBeat
- MapLight Therapeutics Reports Third Quarter Financial Results and Highlights Corporate ProgressGlobeNewswire
- Maplight Therapeutics (NASDAQ:MPLT) was upgraded by analysts at Jefferies Financial Group Inc. to a "strong-buy" rating.MarketBeat
- Maplight Therapeutics (NASDAQ:MPLT) was upgraded by analysts at Zacks Research to a "hold" rating.MarketBeat
- Maplight Therapeutics (NASDAQ:MPLT) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.MarketBeat
MPLT
Sec Filings
- 12/4/25 - Form 10-Q
- 12/4/25 - Form 8-K
- 11/20/25 - Form SCHEDULE
- MPLT's page on the SEC website